Overview

Prophylactic Human Vaccines Market Overview:

Prophylactic human vaccinations enhance the immune response and are meant to reduce the consequences of future pathogen infection in humans. Hepatitis B Virus (HBV) and Human Papilloma Virus (HPV) vaccines are being developed using novel vaccine development methods such as viral-like particles. CureVac AG, for example, earned a EUR 2 million Vaccination Prize from the European Commission for their unique RNActive vaccine technology. This RNActive vaccine technology enables the manufacturing of safe, effective, and cost-efficient vaccinations that are resistant to high temperatures as well as accidental freezing.
During the projected period, the prophylactic human vaccine market is likely to rise due to an increase in pipeline research and increased engagement of major companies in vaccine development. CureVac AG, for example, stated in October 2018 that it will begin a dosage escalation phase I clinical trial for CV7202 mRNA-based rabies vaccine. CV7202 is a preventive vaccination that contains the rabies virus glycoprotein RABV-G. This allows vaccinated individuals' own cells to manufacture RABV-G protein, triggering an immunological response. The investigation is expected to be completed. Furthermore, increased endeavours by various scientists to discover creative ways to combat infectious illnesses are likely to propel market expansion. In September 2018, VBI Vaccines Inc. announced the creation of three Scientific and Clinical Advisory Boards (SABs) comprised of prominent specialists in infectious disease and immuno-oncology research and vaccine development targeting hepatitis B, Cytomegalovirus (CMV), and Glioblastoma (GBM). Because of improved vaccine development, this partnership is projected to fuel market expansion. Significant vaccine development challenges, such as viral variety and a scarcity of animal models, are expected to stymie the expansion of the preventive human vaccination industry. According to Gastroenterology in October 2018, vaccine development demands a large investment from a variety of resources and is quite difficult. Designing human vaccination trials is difficult since the risks of developing an acute illness after inoculation are relatively high. As a result, anti-viral medication must be provided quickly, making illness management difficult.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Prophylactic Human Vaccines Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Prophylactic Human Vaccines Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Prophylactic Human Vaccines Market:
• GlaxoSmithKline Plc.
• Merck and Co., Inc.
• Pfizer, Inc.
• Janssen Pharmaceuticals, Inc.
• Altimmune, Inc.
• Bharat Biotech Limited
• Serum Institute of India, Pvt. Ltd
• Sanofi Pasteur SA
• Shanghai BravoBio Co., Ltd.
• SK Chemicals Co., Ltd.
(Note: The list of the major players will be updated with the latest market scenario and trends)

Prophylactic Human Vaccines Market Segmentation:          
By Vaccine Technology

• Live Attenuated vaccine
• Inactivated Vaccines
• Toxoid Vaccines
• Polysaccharide Vaccines
• Conjugate Vaccines
• Recombinant Vaccines

By Region
• North America
Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Prophylactic Human Vaccines Market By Vaccine Technology and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

$3450

Need Assistance

--------

UK : +44 141 628 9353
US : +1 347 709 4931

OR

Contact Sales

What you get


  • Excel Dataset

  • Infographics

  • PDF Report

  • Market Overview

  • PowerPoint Presentation

What's included


  • Consumer Perception and Procurement

  • Competitive Analysis

  • What’s Next

  • Market Data Forecast

  • Risks and Opportunity Assessment

  • Market Trends and Dynamics